Innovent Biologics (1801) Stock Forecast & Price Target

Compare

21 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

1801 Analyst Ratings

Strong Buy

14 Buy

0 Hold

0 Sell

Based on 14 analysts giving stock ratings to

Innovent

Biologics

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

1801 Stock 12 Month Forecast

Average Price Target

HK$116.57

▲(36.82% Upside)

Based on 14 Wall Street analysts offering 12 month price targets for Innovent Biologics in the last 3 months. The average price target is HK$116.57 with a high forecast of HK$137.43 and a low forecast of HK$105.02. The average price target represents a 36.82% change from the last price of HK$85.20.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"31":"HK$31","138":"HK$138","57.75":"HK$57.8","84.5":"HK$84.5","111.25":"HK$111.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":137.43119910806377,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$137.43</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":116.5686183158,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$116.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":105.02384211314917,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$105.02</span>\n  </div></div>","useHTML":true}}],"tickPositions":[31,57.75,84.5,111.25,138],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,94.8,98.0793230083126,101.35864601662519,104.63796902493779,107.91729203325039,111.19661504156298,114.47593804987558,117.75526105818818,121.03458406650077,124.31390707481337,127.59323008312597,130.87255309143856,134.15187609975118,{"y":137.43119910806377,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,94.8,96.47450910121538,98.14901820243077,99.82352730364615,101.49803640486154,103.17254550607691,104.8470546072923,106.52156370850768,108.19607280972308,109.87058191093845,111.54509101215385,113.21960011336922,114.8941092145846,{"y":116.5686183158,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,94.8,95.58644939331917,96.37289878663833,97.1593481799575,97.94579757327666,98.73224696659584,99.518696359915,100.30514575323417,101.09159514655333,101.8780445398725,102.66449393319166,103.45094332651084,104.23739271983001,{"y":105.02384211314917,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":38.65,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.6,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.75,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.85,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.75,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.1,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":78.4,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":93,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":105.4,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":96.4,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.8,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetHK$137.43

Average Price TargetHK$116.57

Lowest Price TargetHK$105.02

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Matthew Yan

CLSA

HK$120.1

Buy

40.96%

Upside

Reiterated

12/08/25

CLSA Keeps Their Buy Rating on Innovent Biologics (IVBXF)

Unknown Analyst

UBS

Not Ranked

UBS

HK$137.4

Buy

61.27%

Upside

Reiterated

12/08/25

Innovent Biologics (IVBXF) Gets a Buy from UBS

Unknown Analyst

UBS

Not Ranked

UBS

HK$137.4

Buy

61.27%

Upside

Reiterated

11/28/25

Unknown Analyst

Zhongtai Securities

Not Ranked

Zhongtai Securities

HK$116.6

Buy

36.85%

Upside

Reiterated

11/12/25

Unknown Analyst

CCB Intl.

Not Ranked

CCB Intl.

HK$128

Buy

50.23%

Upside

Reiterated

11/06/25

Unknown Analyst

Citic Securities

Not Ranked

Citic Securities

HK$115

Buy

34.98%

Upside

Reiterated

10/27/25

Unknown Analyst

CICC

Not Ranked

CICC

HK$118.3

Buy

38.85%

Upside

Reiterated

10/24/25

Jill Wu

CMB International Securities

HK$109.48→HK$110.62

Buy

29.84%

Upside

Reiterated

10/23/25

Innovent Biologics and Takeda Partnership Fuels Global Expansion and Strengthens Buy Rating

Unknown Analyst

BOCOM International Holdings Company

Not Ranked

BOCOM International Holdings Company

HK$105

Buy

23.24%

Upside

Reiterated

10/23/25

BOCOM International Holdings Company Remains a Buy on Innovent Biologics (IVBXF)

Unknown Analyst

UBS

Not Ranked

UBS

HK$120.1→HK$137.4

Buy

61.27%

Upside

Reiterated

10/22/25

Yang Huang

J.P. Morgan

HK$114→HK$110

Buy

29.11%

Upside

Reiterated

10/22/25

Analysts Conflicted on These Healthcare Names: BioNTech SE (NASDAQ: BNTX), Icon (NASDAQ: ICLR) and Innovent Biologics (Other OTC: IVBXF)

Unknown Analyst

Bank of America Securities

Not Ranked

Bank of America Securities

HK$106.9→HK$113

Buy

32.63%

Upside

Reiterated

10/22/25

Unknown Analyst

Jefferies

Not Ranked

Jefferies

HK$105

Buy

23.24%

Upside

Reiterated

10/08/25

Unknown Analyst

HSBC

Not Ranked

HSBC

HK$115

Buy

34.98%

Upside

Reiterated

09/30/25

Jack Lin

Morgan Stanley

HK$67→HK$123

Buy

44.37%

Upside

Reiterated

09/22/25

Morgan Stanley Sticks to Its Buy Rating for Innovent Biologics (IVBXF)Morgan Stanley analyst Jack Lin raised the price target on Innovent Biologics Inc. (1801:HK) (OTC: IVBXF) to HK$123.00 (from HK$67.00) while maintaining a Overweight rating.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Matthew Yan

CLSA

HK$120.1

Buy

40.96%

Upside

Reiterated

12/08/25

CLSA Keeps Their Buy Rating on Innovent Biologics (IVBXF)

Unknown Analyst

UBS

Not Ranked

UBS

HK$137.4

Buy

61.27%

Upside

Reiterated

12/08/25

Innovent Biologics (IVBXF) Gets a Buy from UBS

Unknown Analyst

UBS

Not Ranked

UBS

HK$137.4

Buy

61.27%

Upside

Reiterated

11/28/25

Unknown Analyst

Zhongtai Securities

Not Ranked

Zhongtai Securities

HK$116.6

Buy

36.85%

Upside

Reiterated

11/12/25

Unknown Analyst

CCB Intl.

Not Ranked

CCB Intl.

HK$128

Buy

50.23%

Upside

Reiterated

11/06/25

Unknown Analyst

Citic Securities

Not Ranked

Citic Securities

HK$115

Buy

34.98%

Upside

Reiterated

10/27/25

Unknown Analyst

CICC

Not Ranked

CICC

HK$118.3

Buy

38.85%

Upside

Reiterated

10/24/25

Jill Wu

CMB International Securities

HK$109.48→HK$110.62

Buy

29.84%

Upside

Reiterated

10/23/25

Innovent Biologics and Takeda Partnership Fuels Global Expansion and Strengthens Buy Rating

Unknown Analyst

BOCOM International Holdings Company

Not Ranked

BOCOM International Holdings Company

HK$105

Buy

23.24%

Upside

Reiterated

10/23/25

BOCOM International Holdings Company Remains a Buy on Innovent Biologics (IVBXF)

Unknown Analyst

UBS

Not Ranked

UBS

HK$120.1→HK$137.4

Buy

61.27%

Upside

Reiterated

10/22/25

Yang Huang

J.P. Morgan

HK$114→HK$110

Buy

29.11%

Upside

Reiterated

10/22/25

Analysts Conflicted on These Healthcare Names: BioNTech SE (NASDAQ: BNTX), Icon (NASDAQ: ICLR) and Innovent Biologics (Other OTC: IVBXF)

Unknown Analyst

Bank of America Securities

Not Ranked

Bank of America Securities

HK$106.9→HK$113

Buy

32.63%

Upside

Reiterated

10/22/25

Unknown Analyst

Jefferies

Not Ranked

Jefferies

HK$105

Buy

23.24%

Upside

Reiterated

10/08/25

Unknown Analyst

HSBC

Not Ranked

HSBC

HK$115

Buy

34.98%

Upside

Reiterated

09/30/25

Jack Lin

Morgan Stanley

HK$67→HK$123

Buy

44.37%

Upside

Reiterated

09/22/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Innovent Biologics

1 Month

xxx

Success Rate

8/11 ratings generated profit

Average Return

+9.40%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 72.73% of your transactions generating a profit, with an average return of +9.40% per trade.

3 Months

xxx

Success Rate

5/6 ratings generated profit

Average Return

+28.12%

reiterated a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 83.33% of your transactions generating a profit, with an average return of +28.12% per trade.

1 Year

Ziyi ChenGoldman Sachs

Success Rate

5/6 ratings generated profit

Average Return

+46.23%

reiterated a buy rating 5 months ago

Copying Ziyi Chen's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +46.23% per trade.

2 Years

xxx

Success Rate

8/9 ratings generated profit

Average Return

+81.76%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 88.89% of your transactions generating a profit, with an average return of +81.76% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

1801 Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 1801 has received 14 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. 1801 average Analyst price target in the past 3 months is 116.57.

Each month's total comprises the sum of three months' worth of ratings.

1801 Financial Forecast

1801 Earnings Forecast

Next quarter’s earnings estimate for 1801 is HK$0.04 with a range of HK$0.04 to HK$0.04. The previous quarter’s EPS was HK$0.56. 1801 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year 1801 has Performed in-line its overall industry.

1801 Sales Forecast

Next quarter’s sales forecast for 1801 is HK$7.27B with a range of HK$7.12B to HK$7.43B. The previous quarter’s sales results were HK$6.39B. 1801 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year 1801 has Performed in-line its overall industry.

1801 Stock Forecast FAQ

What is HK:1801’s average 12-month price target, according to analysts?

Based on analyst ratings, Innovent Biologics’s 12-month average price target is 116.57.

What is HK:1801’s upside potential, based on the analysts’ average price target?

Innovent Biologics has 36.82% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Innovent Biologics a Buy, Sell or Hold?

Innovent Biologics has a consensus rating of Strong Buy, which is based on 14 buy ratings, 0 hold ratings and 0 sell ratings.

What is Innovent Biologics’s share price target?

The average share price target for Innovent Biologics is 116.57. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is HK$137.43 ,and the lowest forecast is HK$105.02. The average share price target represents 36.82% Increase from the current price of HK$85.2.

What do analysts say about Innovent Biologics?

Innovent Biologics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.

How can I buy shares of Innovent Biologics?

To buy shares of HK:1801, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Innovent Biologics (1801) Stock Forecast & Price Target

1801 Analyst Ratings

1801 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Innovent Biologics

1801 Analyst Recommendation Trends

1801 Financial Forecast

1801 Earnings Forecast

1801 Sales Forecast

1801 Stock Forecast FAQ

Detailed List of Analyst Forecasts